The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced gastric cancer.
H. Ohnuma
No relevant relationships to disclose
Y. Sato
No relevant relationships to disclose
T. Takayama
No relevant relationships to disclose
T. Sagawa
No relevant relationships to disclose
M. Hirakawa
No relevant relationships to disclose
K. Harada
No relevant relationships to disclose
T. Nobuoka
No relevant relationships to disclose
K. Hirata
No relevant relationships to disclose
Y. Sato
No relevant relationships to disclose
Y. Takahashi
No relevant relationships to disclose
S. Katsuki
No relevant relationships to disclose
S. Takahashi
No relevant relationships to disclose
M. Hirayama
No relevant relationships to disclose
M. Takahashi
No relevant relationships to disclose
M. Maeda
No relevant relationships to disclose
T. Sato
No relevant relationships to disclose
K. Miyanishi
No relevant relationships to disclose
M. Kobune
No relevant relationships to disclose
R. Takimoto
No relevant relationships to disclose
J. Kato
No relevant relationships to disclose